Objective: Chronic kidney disease (CKD) patients are at high risk of heart failure (HF) and
both share similar risk factors, including diabetes and elevated blood Pressure (BP). Aim of …

Background: It was proved that sacubitril-valsartan has a major role in ventricular
remodeling resulting in improving ejection fraction and ventricular size. Although evaluating …

Objective: To examine the impact of administering low-dose sacubitril-valsartan on the
quality of health in individuals suffering from heart failure and reduced ejection fraction …

Background: Heart failure (HF) is a complicated clinical disease that develops when the Left
ventricular becomes symptomatic due to anatomical or functional ventricular malfunction …

Background Angiotensin receptor blocker and a neprilysin inhibitor (ARNI) has emerged as
an innovative therapy for patients of heart failure with reduced ejection fraction (HFrEF). The …

Background: The prevalence of chronic heart failure (CHF) is up to 1-2% of the adult
population in developed countries, rising to> 10% after the age of 70. Heart failure with …

Background: Sacubitril/Valsartan is one of the pillars of heart failure (HF) management. Little
is known about its uses or impact in real-world practice in the Indian population. We …

Methods: A total of sixty CHF patients were divided randomly into two groups of thirty
patients each (conventional and sacubitril-valsartan groups, respectively). Conventional anti …

Background Impaired renal function is frequently observed in patients with heart failure and
reduced ejection fraction (HFrEF). The differential effect of sacubitril/valsartan and …

Abstract Sacubitril/valsartan (LCZ696) is recommended for ejection fraction reduction in
heart failure. However, studies comparing the effects of sacubitril/valsartan in patients with …